Oncology

Therini Bio's novel drug THN391 enters trials, targeting inflammation in diabetic eye disease, while a next-gen combo therapy aims to redefine care.

EOM Pharmaceutical gets FDA clearance for a trial on EOM613, a potential first-in-class treatment for cancer cachexia, a severe wasting syndrome.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

NEOK Bio begins Phase 1 trials for two bispecific ADCs, a next-gen therapy aiming to outsmart tumor resistance and offer new hope for solid tumor patients.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Free skin cancer screenings in Ottawa highlight a national health crisis as wait times soar and experts demand urgent government action on specialist care.

A new partnership between TD2 Oncology and Panome Bio aims to merge clinical expertise with deep multi-omics data to accelerate personalized cancer therapies.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A landmark approval paves the way for a 200-bed cancer hospital in Nepal's most underserved province, promising hope and advanced care to millions.

John Theurer Cancer Center presents breakthroughs in CAR-T, ADCs, and health equity at ASCO, offering new hope for patients worldwide.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

Triage Cancer and Bright Spot Network launch a free national program offering legal, financial, and emotional support to families facing a parent's illness.

A breakthrough 'pap smear for the pancreas' that detects early cancer has secured major funding, offering new hope against one of the deadliest diseases.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A new report shows hospitals in a federal drug discount program provide less charity care than others, fueling calls for urgent federal reforms.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

Studies reveal an AI platform slashes cancer patient hospitalizations by up to 51% and saves millions, heralding a new era of remote oncology care.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.